Following an industry-wide shift to precision oncology marked by an influx of newly validated patient-derived, in vitro and ex vivo models and regulatory support for alternatives to animal testing, it is imperative to keep up to date with the latest tumour models. As assets only become more complex requiring more advanced testing and with development costs skyrocketing, it has never been more important to share cross-industry learnings in de-risking the move to the clinic.

Returning to London in December 2024, the annual Tumour Models London Summit was home to a community of 180+ industry experts leading Preclinical, Translational, Discovery, Toxicity, and Biology development teams eager to discuss best practices in optimising and implementing more translatable oncology models.

Covering cutting-edge case studies in validating new models, leveraging PDX, optimising forward and reverse translational studies and more from leading companies like AstraZeneca, Bicycle Therapeutics, Johnson & Johnson, Servier, and Gilead Sciences, this event was a one-stop-shop to learn about the latest innovations within the tumour modelling space as well as connect with a room full of  peers with the goal of closing the gap between research and patients.